Loading company…
Basel-based clinical-stage immuno-oncology company developing off-the-shelf and personalized cancer immunotherapies.
Nouscom AG, co-founded by Riccardo Cortese in 2015 and based in Basel, Switzerland, is a clinical-stage immuno-oncology company. Its pipeline includes NOUS-209, an immunotherapy for solid tumors and for prevention in people with Lynch syndrome, and NOUS-PEV, a personalized immunotherapy for cancers. In March 2024 it raised EUR 7 million in an extended Series C from Angelini Ventures, bringing total Series C funding to EUR 75.8 million. CEO Marina Udier leads the company.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in